Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Engineering an oncolytic adenoviral platform for precise delivery of antisense peptide nucleic acid to modulate PD-L1 overexpression in cancer cells.
Falanga AP, Greco F, Terracciano M, D'Errico S, Marzano M, Feola S, Sepe V, Fontana F, Piccialli I, Cerullo V, Santos HA, Borbone N. Falanga AP, et al. Among authors: feola s. Int J Pharm. 2025 Jan 5;668:124941. doi: 10.1016/j.ijpharm.2024.124941. Epub 2024 Nov 10. Int J Pharm. 2025. PMID: 39532274 Free article.
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses.
Feodoroff M, Hamdan F, Antignani G, Feola S, Fusciello M, Russo S, Chiaro J, Välimäki K, Pellinen T, Branca RM, Lehtiö J, D Alessio F, Bottega P, Stigzelius V, Sandberg J, Clancy J, Partanen J, Malmstedt M, Rannikko A, Pietiäinen V, Grönholm M, Cerullo V. Feodoroff M, et al. Among authors: feola s. Oncoimmunology. 2024 Sep 25;13(1):2407532. doi: 10.1080/2162402X.2024.2407532. eCollection 2024. Oncoimmunology. 2024. PMID: 39351443 Free PMC article.
Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses.
Harjunpää H, Somermäki R, Saldo Rubio G, Fusciello M, Feola S, Faisal I, Nieminen AI, Wang L, Llort Asens M, Zhao H, Eriksson O, Cerullo V, Fagerholm SC. Harjunpää H, et al. Among authors: feola s. Oncoimmunology. 2024 Jun 21;13(1):2369373. doi: 10.1080/2162402X.2024.2369373. eCollection 2024. Oncoimmunology. 2024. PMID: 38915784 Free PMC article.
Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.
Russo S, Feola S, Feodoroff M, Chiaro J, Antignani G, Fusciello M, D'Alessio F, Hamdan F, Pellinen T, Mölsä R, Tripodi L, Pastore L, Grönholm M, Cerullo V. Russo S, et al. Among authors: feola s. Mol Ther Oncol. 2024 Jan 26;32(1):200766. doi: 10.1016/j.omton.2024.200766. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596301 Free PMC article.
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D'Alessio F, Mölsä R, Stigzelius V, Bottega P, Pesonen S, Leusen J, Grönholm M, Cerullo V. Feola S, et al. J Immunother Cancer. 2024 Mar 8;12(3):e008342. doi: 10.1136/jitc-2023-008342. J Immunother Cancer. 2024. PMID: 38458776 Free PMC article.
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.
Feola S, Chiaro J, Fusciello M, Russo S, Kleino I, Ylösmäki L, Kekäläinen E, Hästbacka J, Pekkarinen PT, Ylösmäki E, Capone S, Folgori A, Raggioli A, Boni C, Tiezzi C, Vecchi A, Gelzo M, Kared H, Nardin A, Fehlings M, Barban V, Ahokas P, Viitala T, Castaldo G, Pastore L, Porter P, Pesonen S, Cerullo V. Feola S, et al. Int J Biol Macromol. 2024 Mar;262(Pt 1):129926. doi: 10.1016/j.ijbiomac.2024.129926. Epub 2024 Feb 6. Int J Biol Macromol. 2024. PMID: 38331062
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.
Manfredi F, Stasi L, Buonanno S, Marzuttini F, Noviello M, Mastaglio S, Abbati D, Potenza A, Balestrieri C, Cianciotti BC, Tassi E, Feola S, Toffalori C, Punta M, Magnani Z, Camisa B, Tiziano E, Lupo-Stanghellini MT, Branca RM, Lehtiö J, Sikanen TM, Haapala MJ, Cerullo V, Casucci M, Vago L, Ciceri F, Bonini C, Ruggiero E. Manfredi F, et al. Among authors: feola s. Sci Adv. 2023 Dec;9(48):eadg8014. doi: 10.1126/sciadv.adg8014. Epub 2023 Dec 1. Sci Adv. 2023. PMID: 38039364 Free PMC article.
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, Rescigno M, Grönholm M, Branca RM, Lehtiö J, Cerullo V. Chiaro J, et al. Among authors: feola s. Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7. Nat Commun. 2023. PMID: 37923723 Free PMC article.
First terror bird footprints reveal functionally didactyl posture.
Melchor RN, Feola SF, Cardonatto MC, Espinoza N, Rojas-Manriquez MA, Herazo L. Melchor RN, et al. Among authors: feola sf. Sci Rep. 2023 Sep 30;13(1):16474. doi: 10.1038/s41598-023-43771-x. Sci Rep. 2023. PMID: 37777554 Free PMC article.
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.
Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, Coluccino L, Vitale M, Scalia G, Gentile L, De Lorenzo C, Guarracino MR, Castaldo G, D'Argenio V, Szomolay B, Cerullo V, Pastore L. Tripodi L, et al. Among authors: feola s. iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20. iScience. 2023. PMID: 37720092 Free PMC article.
38 results